Philip Band

Philip Band, PhD, is a prominent figure in the fields of orthopaedic surgery, biochemistry, and molecular pharmacology. Currently serving as the Chief Executive Officer of CytoDel LLC since June 2015, Philip Band leads a company focused on commercializing innovative technology aimed at delivering therapeutic agents to neurons. Concurrently, Philip Band holds the position of Research Professor at NYU School of Medicine, where research efforts are concentrated on knee osteoarthritis biomarkers and their implications for clinical decision-making. As Co-Director of the NYU Joint Preservation and Arthritis Center, Philip Band oversees initiatives to optimize conservative treatments for knee osteoarthritis. Previous roles include Director of the Center for Clinical Research at NYU Hospital for Joint Diseases and Vice President of Research at Biomatrix. Philip Band's academic journey includes a post-doctoral fellowship at NYU School of Medicine, and educational background from The City University of New York.